Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emenean
- Development stage
- Unknown
- Lead developer
- DRS Biopharma
- Modality
- Small Molecules
- Administration
- Oral, Buccal, Sublingual
01
Overview
Emenean is an orally disintegrating film (ODF) formulation of ondansetron, a selective 5-HT3 receptor antagonist. Developed by DRS Biopharma, it is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). The ODF technology allows the medication to dissolve rapidly on the tongue without the need for water, providing a convenient administration route for patients suffering from emesis or dysphagia. By blocking serotonin at 5-HT3 receptors on vagal nerve terminals and in the chemoreceptor trigger zone of the central nervous system, it effectively suppresses the vomiting reflex.
- Brand names
- Emenean
- Other names
- Ondansetron 4mg ODFOndansetron4mg ODFOndansetron-4mg ODFondansetron
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on Emenean.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Emenean.